Home › Research › Laboratory science
CD103-CD8+ T cells promote neurotoxic inflammation in Alzheimer's disease via granzyme K-PAR-1 signaling
Terrabuio E, Pietronigro EC, Bani A, Della Bianca V, Laudanna C, Rossi B, Finotti G, Santos-Lima B, Zenaro E, Turano E, Tosadori G, Calgaro M, et al.. Nature Communications, 2025-09-24
Topic: Brain proteins, microglia and lab models
Plain-language summary
Immune mechanisms contribute to the neuropathology of Alzheimer's disease (AD) but the role of adaptive immune cells is unclear. Here we show that the brain CD8 + T cell compartment is dysregulated in AD patients and in the 3xTg-AD mouse model, accumulating activated CD103 - tissue-resident memory T cells that produce large amounts of granzyme K (GrK). These CD103 - CD8 + T cells originate from the circulation and migrate into the brain using LFA-1 integrin. Ablation of brain CD103 - CD8 + T cells in 3xTg-AD mice ameliorates cognitive decline and reduces neuropathology. GrK induces neuronal dysfunction and tau hyperphosphorylation in human and mouse cells via protease-activated receptor-1 (PAR-1), which is expressed at higher levels in the AD brain, revealing a key immune-mediated neurotoxic axis. We conclude that communication between CD8 + T cells and the nervous system is altered in AD, paving the way for therapies targeting T cell-dependent neurotoxic inflammation.
What this study adds
Evidence grade: Early
In a mouse model, removing certain brain CD8 T cells improved cognition and reduced neuropathology, and a signaling pathway involving granzyme K and PAR-1 was identified. This is early animal and cell work pointing to a possible target, not a treatment for patients.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Terrabuio, E., Pietronigro, E. C., Bani, A., Della Bianca, V., Laudanna, C., Rossi, B., et al. (2025). CD103-CD8+ T cells promote neurotoxic inflammation in Alzheimer's disease via granzyme K-PAR-1 signaling. Nature Communications. https://doi.org/10.1038/s41467-025-62405-6
Vancouver
Terrabuio E, Pietronigro EC, Bani A, Della Bianca V, Laudanna C, Rossi B, et al. CD103-CD8+ T cells promote neurotoxic inflammation in Alzheimer's disease via granzyme K-PAR-1 signaling. Nature Communications. 2025. doi:10.1038/s41467-025-62405-6. PMID: 40993111.
BibTeX
@article{terrabuio2025-40993111,
author = {Terrabuio, E. and Pietronigro, E. C. and Bani, A. and Della Bianca, V. and Laudanna, C. and Rossi, B. and Finotti, G. and Santos-Lima, B. and Zenaro, E. and Turano, E. and Tosadori, G. and Calgaro, M. and others},
title = {{CD103-CD8+ T cells promote neurotoxic inflammation in Alzheimer's disease via granzyme K-PAR-1 signaling}},
journal = {Nature Communications},
year = {2025},
doi = {10.1038/s41467-025-62405-6},
pmid = {40993111},
url = {https://doi.org/10.1038/s41467-025-62405-6}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- We conclude that communication between CD8 + T cells and the nervous system is altered in AD, paving the way for therapies targeting T cell-dependent neurotoxic inflammation.
Why it matters
In a mouse model, removing certain brain CD8 T cells improved cognition and reduced neuropathology, and a signaling pathway involving granzyme K and PAR-1 was identified. This is early animal and cell work pointing to a possible target, not a treatment for patients.
Study details
- Evidence strengthEarly
How this study scored 47/100
Published in a leading specialty journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it. We have no data on free to read, so that was left out: it earned 46 of the 98 points we could judge it on, which is 47 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (Nature Communications) |
| Journal's citation record | 4 / 4 | Nature Communications: journal h-index 747 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 2 / 5 | Rated “early” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 3 / 7 | Cited 23 times (OpenAlex, 2026-10-10) |
| Citations per year | 2 / 5 | 7.7 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 4 / 6 | Cited 12.6× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 2 / 4 | Cited 23 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 2 / 4 | Last-listed author Gabriela Constantin: h-index 47 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Verona: institution h-index 763 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40993111) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 46 / 98 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 46 of the 98 points we could judge it on is 47 out of 100. |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Laboratory science from nearby years
Also tagged “tdp-43”
1,150 studies in the library carry the topic tag “tdp-43”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,150 tagged studies.